Literature DB >> 34141459

Erratum: LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.

Hien Tran Zhao, Neena John, Vedad Delic, Karli Ikeda-Lee, Aneeza Kim, Andreas Weihofen, Eric E Swayze, Holly B Kordasiewicz, Andrew B West, Laura A Volpicelli-Daley.   

Abstract

[This corrects the article DOI: 10.1016/j.omtn.2017.08.002.].
© 2021 The Author(s).

Entities:  

Year:  2021        PMID: 34141459      PMCID: PMC8170353          DOI: 10.1016/j.omtn.2021.05.013

Source DB:  PubMed          Journal:  Mol Ther Nucleic Acids        ISSN: 2162-2531            Impact factor:   8.886


(Mol Ther Nucleic Acids. 8, 508–519; September 15, 2017) In the originally published version of this article, in Figure 1B, the immunoblot of the LRRK2 protein for the ASO2 was inadvertently duplicated for ASO1. In Figure S2, the HSC70 loading control for the ASO1 was inadvertently duplicated for ASO2. The figure panel images have been corrected to show the actual representative blots that were used for quantification. The authors regret this error. Identification of Efficacious LRRK2 ASOs that Reduce Formation of α-Syn Inclusions Dose-dependent reduction of Lrrk2 mRNA and LRRK2 protein in the cortex in LRRK2 ASO-treated mice
  1 in total

1.  Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.

Authors:  Ranjan K Singh; Ahmed Soliman; Giambattista Guaitoli; Eliza Störmer; Felix von Zweydorf; Thomas Dal Maso; Asmaa Oun; Laura Van Rillaer; Sven H Schmidt; Deep Chatterjee; Joshua A David; Els Pardon; Thomas U Schwartz; Stefan Knapp; Eileen J Kennedy; Jan Steyaert; Friedrich W Herberg; Arjan Kortholt; Christian Johannes Gloeckner; Wim Versées
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-01       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.